MediPharm Labs Corp. (TSX: LABS)
Canada
· Delayed Price · Currency is CAD 0.0650
0.00 (0.00%)
Dec 20, 2024, 2:27 PM EST
MediPharm Labs Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 39.05 | 33.06 | 22.12 | 21.71 | 36.01 | 129.25 | Upgrade
|
| Revenue Growth (YoY) | 32.16% | 49.49% | 1.87% | -39.71% | -72.14% | 1167.42% | Upgrade
|
| Cost of Revenue | 25.34 | 24.96 | 24.19 | 35.13 | 74.88 | 89.82 | Upgrade
|
| Gross Profit | 13.71 | 8.1 | -2.07 | -13.42 | -38.86 | 39.44 | Upgrade
|
| Selling, General & Admin | 20.05 | 20.19 | 24.4 | 30.87 | 27.81 | 30.71 | Upgrade
|
| Research & Development | 0.39 | 0.29 | 1.12 | 1.51 | 2.21 | 0.87 | Upgrade
|
| Other Operating Expenses | -0.97 | 0.07 | 0.17 | -0.07 | 0.53 | 0.03 | Upgrade
|
| Operating Expenses | 19.48 | 20.54 | 25.7 | 32.3 | 30.55 | 31.6 | Upgrade
|
| Operating Income | -5.77 | -12.44 | -27.77 | -45.72 | -69.41 | 7.83 | Upgrade
|
| Interest Expense | -0.66 | -0.37 | -0.03 | -10.51 | -7.88 | -0.44 | Upgrade
|
| Interest & Investment Income | 0.82 | 0.84 | 0.48 | 0.23 | 0.27 | 0.49 | Upgrade
|
| Currency Exchange Gain (Loss) | -1 | -0.46 | -0.74 | -1.67 | 1.18 | -0.41 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0 | 4.51 | 8.08 | -0.24 | Upgrade
|
| EBT Excluding Unusual Items | -6.61 | -12.42 | -28.06 | -53.16 | -67.76 | 7.23 | Upgrade
|
| Merger & Restructuring Charges | -5.31 | -5.31 | -1.04 | - | -1.25 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.08 | -0.08 | -0.91 | - | - | -0.48 | Upgrade
|
| Asset Writedown | -0.04 | -0.22 | - | -6.29 | -7.6 | - | Upgrade
|
| Other Unusual Items | - | 4.67 | 0.02 | 4.76 | 4.51 | - | Upgrade
|
| Pretax Income | -12.03 | -13.36 | -29.99 | -54.69 | -72.1 | 6.75 | Upgrade
|
| Income Tax Expense | -0.27 | -0.28 | -0.01 | 0.11 | -4.99 | 5.62 | Upgrade
|
| Earnings From Continuing Operations | -11.76 | -13.08 | -29.98 | -54.8 | -67.11 | 1.13 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.76 | 0.51 | Upgrade
|
| Net Income | -11.76 | -13.08 | -29.98 | -54.8 | -66.35 | 1.65 | Upgrade
|
| Net Income to Common | -11.76 | -13.08 | -29.98 | -54.8 | -66.35 | 1.65 | Upgrade
|
| Shares Outstanding (Basic) | 399 | 363 | 277 | 250 | 139 | 120 | Upgrade
|
| Shares Outstanding (Diluted) | 399 | 363 | 277 | 250 | 139 | 135 | Upgrade
|
| Shares Change (YoY) | 16.60% | 31.23% | 10.79% | 80.37% | 2.91% | 85.46% | Upgrade
|
| EPS (Basic) | -0.03 | -0.04 | -0.11 | -0.22 | -0.48 | 0.01 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.04 | -0.11 | -0.22 | -0.48 | 0.01 | Upgrade
|
| Free Cash Flow | -2.55 | -12.81 | -16.93 | -14 | -45.28 | -57.61 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.04 | -0.06 | -0.06 | -0.33 | -0.43 | Upgrade
|
| Gross Margin | 35.10% | 24.50% | -9.38% | -61.81% | -107.92% | 30.51% | Upgrade
|
| Operating Margin | -14.78% | -37.63% | -125.56% | -210.59% | -192.75% | 6.06% | Upgrade
|
| Profit Margin | -30.10% | -39.57% | -135.57% | -252.41% | -184.25% | 1.27% | Upgrade
|
| Free Cash Flow Margin | -6.53% | -38.75% | -76.56% | -64.47% | -125.72% | -44.57% | Upgrade
|
| EBITDA | -3.17 | -10.03 | -24.99 | -40.42 | -59.03 | 10.19 | Upgrade
|
| EBITDA Margin | -8.13% | -30.35% | -112.99% | -186.17% | -163.91% | 7.88% | Upgrade
|
| D&A For EBITDA | 2.6 | 2.41 | 2.78 | 5.3 | 10.39 | 2.36 | Upgrade
|
| EBIT | -5.77 | -12.44 | -27.77 | -45.72 | -69.41 | 7.83 | Upgrade
|
| EBIT Margin | -14.78% | -37.63% | -125.56% | -210.59% | -192.75% | 6.06% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 83.25% | Upgrade
|
| Revenue as Reported | 39.05 | 33.06 | 22.12 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.